CD276 and neoplasm: Although the other two BiCisCAR variants exhibited comparable tumor clearance in RH30 and RMS559 IM tumors, the FGFR4.28HTM.28z-CD276.8HTM.BBz BiCisCAR, incorporating different CSDs, not only cleared tumors more rapidly but also exhibited robust antitumor activity in a stressful RMS559 orthotopic model with only 1 million CAR T-cells administered.